CA2282654C - Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder - Google Patents

Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder Download PDF

Info

Publication number
CA2282654C
CA2282654C CA002282654A CA2282654A CA2282654C CA 2282654 C CA2282654 C CA 2282654C CA 002282654 A CA002282654 A CA 002282654A CA 2282654 A CA2282654 A CA 2282654A CA 2282654 C CA2282654 C CA 2282654C
Authority
CA
Canada
Prior art keywords
group
indanon
benzyl
attention
methylpiperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002282654A
Other languages
English (en)
French (fr)
Other versions
CA2282654A1 (en
Inventor
Sharon L. Rogers
Lawrence T. Friedhoff
Paul J. Tiseo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of CA2282654A1 publication Critical patent/CA2282654A1/en
Application granted granted Critical
Publication of CA2282654C publication Critical patent/CA2282654C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002282654A 1997-03-03 1998-03-03 Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder Expired - Fee Related CA2282654C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3983297P 1997-03-03 1997-03-03
US60/039,832 1997-03-03
PCT/IB1998/000508 WO1998039000A1 (en) 1997-03-03 1998-03-03 Use of cholinesterase inhibitors to treat disorders of attention

Publications (2)

Publication Number Publication Date
CA2282654A1 CA2282654A1 (en) 1998-09-11
CA2282654C true CA2282654C (en) 2009-02-03

Family

ID=21907565

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002282654A Expired - Fee Related CA2282654C (en) 1997-03-03 1998-03-03 Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder

Country Status (12)

Country Link
US (2) US6455544B1 (https=)
EP (1) EP0971713B1 (https=)
JP (1) JP4095676B2 (https=)
AT (1) ATE241358T1 (https=)
AU (1) AU743609B2 (https=)
CA (1) CA2282654C (https=)
DE (1) DE69815090T2 (https=)
DK (1) DK0971713T3 (https=)
ES (1) ES2200313T3 (https=)
NZ (1) NZ337515A (https=)
PT (1) PT971713E (https=)
WO (1) WO1998039000A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0971713B1 (en) * 1997-03-03 2003-05-28 Eisai Co., Ltd. Use of cholinesterase inhibitors to treat disorders of attention
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
US6429207B1 (en) 1997-11-21 2002-08-06 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
EP1311272B1 (en) 2000-03-03 2006-11-22 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
EP1764101A1 (en) * 2000-03-03 2007-03-21 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
JP2006516948A (ja) * 2000-11-14 2006-07-13 ニュー リバー ファーマシューティカルズ インコーポレイテッド 硫酸アバカビルを含有する新規な薬剤化合物および同化合物の製造ならびに使用方法
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
DK1531822T3 (da) 2002-06-12 2009-12-07 Chemocentryx Inc 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
US7435830B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
JP4696062B2 (ja) * 2004-04-28 2011-06-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 １−ベンジル−４−［（５，６−ジメトキシ−１−インダノン）−２−イル］メチルピペリジンおよびその塩酸塩の製造法
WO2006036936A2 (en) * 2004-09-27 2006-04-06 Bridge Pharma, Inc. The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
US20060079558A1 (en) * 2004-09-27 2006-04-13 Bridge Pharma. Inc. R-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics
CA2589102C (en) 2004-11-02 2013-08-13 Northwestern University Pyridazine compounds and methods for using the compounds to treat inflammatory diseases
WO2006081332A1 (en) * 2005-01-25 2006-08-03 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
US20060270709A1 (en) * 2005-04-04 2006-11-30 Eisai Co. Ltd. Dihydropyridine compounds and compositions for headaches
CA2624805A1 (en) * 2005-10-14 2007-04-19 Eisai R&D Management Co., Ltd. Process for producing 1-benzyl-4-[(5,6-dimethoxy-1­indanon)-2-yl]methylpiperidine or hydrochloride thereof
CN101410374A (zh) * 2005-11-14 2009-04-15 麦迪凯姆股份公司 用于制备盐酸多奈哌齐的中间体和其新多晶型物的改良的合成和制备
CA2650711A1 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
US7592458B2 (en) * 2006-07-21 2009-09-22 Wright George E Dermal anesthetic compounds and pharmaceutical compositions for inducing local anesthesia and mitigating neuropathic pain
US20100048628A1 (en) * 2006-12-01 2010-02-25 Sumiyo Nishi Method for suppressing discoloration over time of adhesive preparation containing donepezil
JP5237112B2 (ja) * 2006-12-01 2013-07-17 日東電工株式会社 経皮吸収製剤
US20100099714A1 (en) * 2007-03-05 2010-04-22 Eisai R&D Management Co., Ltd. AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
EP2148673A1 (en) * 2007-04-26 2010-02-03 Eisai R&D Management Co., Ltd. Cinnamide compounds for dementia
KR100914691B1 (ko) * 2007-08-10 2009-08-28 주식회사유한양행 도네페질 또는 그의 제조용 중간체의 제조방법
KR20110020788A (ko) * 2008-05-30 2011-03-03 에자이 알앤드디 매니지먼트 가부시키가이샤 경피 흡수 제제
WO2009145177A1 (ja) * 2008-05-30 2009-12-03 日東電工株式会社 ドネペジル含有貼付製剤およびその包装体
EA202092673A3 (ru) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US9637450B2 (en) 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
EP2968304B1 (en) 2013-03-14 2018-10-10 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
EP4036094B1 (en) 2014-04-30 2025-12-24 The Trustees of Columbia University in the City of New York Substituted 4-phenylpiperidines, their preparation and use
KR101732776B1 (ko) * 2014-10-08 2017-05-04 영남대학교 산학협력단 신규한 인데노 피리디니움 유도체 화합물 및 이의 제조방법
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5064858A (en) * 1988-08-17 1991-11-12 Spectrum Pharmaceutical Corporation Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and Alzheimer's disease
WO1997003671A1 (en) * 1995-07-14 1997-02-06 Medeva Europe Limited Composition comprising d-threo-methylphenidate and another drug
SI9720038B (sl) * 1996-06-07 2010-06-30 Eisai Co Ltd Polimorfi donepezil hidroklorida in postopek izdelave
EP0971713B1 (en) * 1997-03-03 2003-05-28 Eisai Co., Ltd. Use of cholinesterase inhibitors to treat disorders of attention

Also Published As

Publication number Publication date
US7105540B2 (en) 2006-09-12
JP2001515480A (ja) 2001-09-18
DE69815090T2 (de) 2004-02-19
NZ337515A (en) 2002-07-26
US6455544B1 (en) 2002-09-24
PT971713E (pt) 2003-09-30
EP0971713A1 (en) 2000-01-19
DK0971713T3 (da) 2003-09-22
WO1998039000A1 (en) 1998-09-11
JP4095676B2 (ja) 2008-06-04
EP0971713B1 (en) 2003-05-28
CA2282654A1 (en) 1998-09-11
ATE241358T1 (de) 2003-06-15
DE69815090D1 (de) 2003-07-03
ES2200313T3 (es) 2004-03-01
AU7321598A (en) 1998-09-22
AU743609B2 (en) 2002-01-31
US20030055040A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
CA2282654C (en) Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder
CA2241611C (en) Chronic, bolus administration of d-threo methylphenidate
US20020035128A1 (en) Methods for treating parkinson's disease
CA2453510C (en) Treatment of fatigue and cognitive side effects associated with cancer, cancer treatments and menopause with d-threo-methyphenidate
KR890000465A (ko) 환상 아민 화합물
HU213271B (en) Process for producing (+)-alpha-(2,3-dimethoxi-phenyl)-1-[2-(4-fluoric-phenyl)-ethyl]-4-piperidine-methanole and pharmaceutical compositions containing the same
JP2007512338A (ja) Ｌ型カルシウムチャンネルブロッカーとコリンエステラーゼ阻害剤を用いた組成物及び処置方法
US20030153598A1 (en) Methods for treating Parkinson's disease with cholinesterase inhibitors
EP0888114B1 (en) Use of (+)-alpha-(2,3-dimethoxyphenyl)-1- 2-(4-fluorophenyl)ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders
JPH0421670A (ja) 光学活性インダノン誘導体
EA003255B1 (ru) Комбинация производных тетрагидропиридинов и ингибиторов ацетилхолинэстеразы для лечения старческой деменции по типу альцгеймера
CA2168265C (en) Antidepressant
WO2000003714A1 (en) Medicinal product and method for treatment and prevention of dyskinesia
KR100682799B1 (ko) Ｒ(+)-α-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올의 수면 장애 치료용 약제학적 조성물
HK1019702B (en) Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(-4-fluorophenyl)ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170303